Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shozo Osera is active.

Publication


Featured researches published by Shozo Osera.


Cancer Science | 2016

Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.

Kenji Tamura; Hirofumi Mukai; Yoichi Naito; Kan Yonemori; Makoto Kodaira; Yuko Tanabe; Noboru Yamamoto; Shozo Osera; Masaoki Sasaki; Yuko Mori; Satoshi Hashigaki; Takashi Nagasawa; Yoshiko Umeyama; Takayuki Yoshino

This phase I study in Japanese patients evaluated the safety, pharmacokinetics, and preliminary efficacy of palbociclib, a highly selective and reversible oral cyclin‐dependent kinase 4/6 inhibitor, as monotherapy for solid tumors (part 1) and combined with letrozole as first‐line treatment of postmenopausal patients with estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer (part 2). Part 1 evaluated palbociclib 100 and 125 mg once daily (3 weeks on/1 week off; n = 6 each group) to determine the maximum tolerated dose. Part 2 evaluated palbociclib maximum tolerated dose (125 mg) plus letrozole 2.5 mg (n = 6). The most common treatment‐related adverse event was neutropenia (all grades/grade 3/4): 100 mg, 83%/67%; 125 mg, 67%/33%; and palbociclib plus letrozole, 100%/83%. Heavier pretreatment with chemotherapy may have resulted in higher neutropenia rates observed with the 100‐mg dose. Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration–time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]). Half‐life was 23–26 h. No drug–drug interactions between palbociclib and letrozole occurred. Four patients had stable disease (≥24 weeks in one patient with rectal cancer [100 mg] and one with esophageal cancer [125 mg]) in part 1; two patients had partial response and two had stable disease (both ≥24 weeks) in part 2. Palbociclib at the 125‐mg dose (schedule 3/1) was tolerated and is the recommended dose for monotherapy and letrozole combination therapy in Japanese patients. The trials are registered with www.ClinicalTrials.gov: A5481010 and NCT01684215.


Endoscopy International Open | 2016

Prophylactic steroid administration for strictures after endoscopic resection of large superficial esophageal squamous cell carcinoma

Tomohiro Kadota; Tomonori Yano; Tomoji Kato; Maomi Imajoh; Masaaki Noguchi; Hiroyuki Morimoto; Shozo Osera; Yusuke Yoda; Yasuhiro Oono; Hiroaki Ikematsu; Atsushi Ohtsu; Kazuhiro Kaneko

Background and study aims: One of the major complications after endoscopic resection (ER) for large superficial esophageal squamous cell carcinoma (ESCC) is benign esophageal stricture, which can reduce quality of life even if ESCC achieves a cure without organ resection. Recently, steroid administration has been reported as a prophylactic treatment to prevent esophageal strictures. This retrospective study evaluated the stricture rate according to the different width of mucosal defects due to ER and compared it to that seen with prophylactic steroid administration. Patients and methods: Between June 2007 and December 2013, we enrolled patients with ESCC who had 3/4 or larger circumferential mucosal defects due to ER. In December 2009, steroid injections (triamcinolone acetonide 50 mg) into the ulcer bed due to ER were introduced. Beginning in November 2012, we commenced oral steroid administration (prednisolone 30 mg/day, tapered gradually for 8 weeks) in addition to steroid injection. Patients were classified into 3 groups according to the width of mucosal defect after ER (Group A, ≥ 3/4 and < 7/8; Group B, ≥ 7/8 and less than the entire circumference; and Group C, the entire circumference). We retrospectively evaluated the stricture rate by comparing no treatment, steroid injection, or steroid injection followed by oral steroid according to the width of mucosal defect. Results: A total of 115 patients met the selection criteria. In Group B, no treatment had a significantly higher stricture rate (100 %, vs. steroid injection: 56 % P = 0.015; vs steroid injection followed by oral steroid: 20 % P < 0.001). Conversely, in Group C, the stricture rate was high, regardless of treatment (no treatment: 100 %; steroid injection: 100 %; steroid injection followed by oral steroid: 71 %). Conclusions: Although prophylactic steroid administration is effective to prevent strictures for 7/8 circumference or larger mucosal defects, it is ineffective for whole-circumference defects. Further investigation is required.


Gastrointestinal Endoscopy | 2015

Efficacy and safety of endoscopic radial incision and cutting for benign severe anastomotic stricture after surgery for lower rectal cancer (with video)

Shozo Osera; Hiroaki Ikematsu; Tomoyuki Odagaki; Yasuhiro Oono; Tomonori Yano; Akihiro Kobayashi; Masaaki Ito; Norio Saito; Kazuhiro Kaneko

Surgical treatment for lower rectal cancer typically comprises intersphincteric resection (ISR), low anterior resection (LAR), and/or abdominoperineal resection. However, as compared with abdominoperineal resection, ISR and LAR can prevent the need for permanent colostomy to a greater extent. With all the above-mentioned procedures, the occurrence of anastomotic strictures is a potential serious postoperative adverse event that typically requires repeated treatment. Balloon dilatation (BD) or bougie dilatation is generally performed to treat anastomotic strictures of the lower rectum; however, the frequency of restenosis is high. Although radial incision and cutting (RIC) when using an electrosurgical insulated-tip knife has been reported to be effective for treating refractory anastomotic strictures after esophagectomy, there are no reports concerning the safety or efficacy of RIC for anastomotic strictures after ISR or LAR. Therefore, in this retrospective case series, we evaluated the efficacy and safety of RIC for severe anastomotic strictures in the lower rectum after ISR or LAR.


Endoscopy International Open | 2017

Visual assessment of colorectal flat and depressed lesions by using narrow band imaging

Hiroshi Nakamura; Hiroaki Ikematsu; Shozo Osera; Renma Ito; Daiki Sato; Tatsunori Minamide; Naoki Okamoto; Yoichi Yamamoto; Takuya Hombu; Kenji Takashima; Keiichiro Nakajo; Tomohiro Kadota; Yusuke Yoda; Keisuke Hori; Yasuhiro Oono; Tomonori Yano

Background and study aims  Visual assessment of laterally spreading tumors non-granular type (LST-NG) and depressed lesions by narrow band imaging (NBI) without magnification has not been studied. We investigated the role of non-magnifying NBI in detecting LST-NG and type IIc lesions on colonoscopy. Patients and methods  This retrospective study examined consecutive patients diagnosed as having LST-NG and/or type IIc lesions in our hospital between August 2011 and July 2013. These lesions were classified as “Brownish area (BA),” “Brown only in the margins (O-ring sign),” “Same color as the normal mucosa (SC),” and “Whitish area (WA)” based on their appearance on non-magnifying NBI, and their appearance were compared with their histopathological findings. Results  A total of 18 type IIc and 180 LST-NG lesions were analyzed. Among the type IIc lesions, 5 (28 %), 12 (67 %), and 1 (5 %) were classified as BA, O-ring sign, and SC, respectively. Among the LST-NG lesions, 126 (70 %), 26 (14 %), and 28 lesions (16 %) were classified as BA, O-ring sign, and SC, respectively. The IIc lesions were found to have 1 lesion (20 %) with high-grade dysplasia (HGD) in the BA, and 2 lesions (17 %) with invasive cancer (IC) in the O-ring sign group. Among the LST-NG lesions, 27 (21 %) were found to have IC and 49 (39 %), HGD in the BA group; 8 lesions (31 %) had IC and 4 (15 %) had HGD in the O-ring sign group; and 1 lesion (4 %) had IC and 4 (14 %) had HGD in the SC group. Conclusions  Most flat and depressed colorectal lesions were seen on non-magnifying NBI as brown lesions with the exception of some flat lesions that were indistinguishable in color from the adjacent normal mucosa. Some of these flat lesions were also found to have HGD or IC.


Gastrointestinal Endoscopy | 2017

Detectability of colorectal neoplastic lesions using a novel endoscopic system with blue laser imaging: a multicenter randomized controlled trial

Hiroaki Ikematsu; Taku Sakamoto; Kazutomo Togashi; Naohisa Yoshida; Takashi Hisabe; Shinsuke Kiriyama; Koji Matsuda; Yoshikazu Hayashi; Takahisa Matsuda; Shozo Osera; Kazuhiro Kaneko; Kenichi Utano; Yuji Naito; Hiroshi Ishihara; Masayuki Kato; Kenichi Yoshimura; Hideki Ishikawa; Hironori Yamamoto; Yutaka Saito


International Journal of Colorectal Disease | 2014

Clinicopathological differences of laterally spreading tumors arising in the colon and rectum

Hideaki Miyamoto; Hiroaki Ikematsu; Satoshi Fujii; Shozo Osera; Tomoyuki Odagaki; Yasuhiro Oono; Tomonori Yano; Atsushi Ochiai; Yutaka Sasaki; Kazuhiro Kaneko


Surgical Endoscopy and Other Interventional Techniques | 2016

Endoscopic submucosal resection with a ligation device for the treatment of duodenal neuroendocrine tumors

Shozo Osera; Yasuhiro Oono; Hiroaki Ikematsu; Tomonori Yano; Kazuhiro Kaneko


World Journal of Gastroenterology | 2017

Risk factors for intraoperative perforation during endoscopic submucosal dissection of superficial esophageal squamous cell carcinoma

Masaaki Noguchi; Tomonori Yano; Tomoji Kato; Tomohiro Kadota; Maomi Imajoh; Hiroyuki Morimoto; Shozo Osera; Atsushi Yagishita; Tomoyuki Odagaki; Yusuke Yoda; Yasuhiro Oono; Hiroaki Ikematsu; Kazuhiro Kaneko


Endoscopy | 2016

Clinicopathological, endoscopic, and molecular characteristics of the “skirt” – a new entity of lesions at the margin of laterally spreading tumors

Shozo Osera; Satoshi Fujii; Hiroaki Ikematsu; Hideaki Miyamoto; Yasuhiro Oono; Tomonori Yano; Atsushi Ochiai; Takayuki Yoshino; Atsushi Ohtsu; Kazuhiro Kaneko


Gastrointestinal Endoscopy | 2017

Endoscopic treatment outcomes of laterally spreading tumors with a skirt (with video)

Shozo Osera; Hiroaki Ikematsu; Satoshi Fujii; Keisuke Hori; Yasuhiro Oono; Tomonori Yano; Kazuhiro Kaneko

Collaboration


Dive into the Shozo Osera's collaboration.

Top Co-Authors

Avatar

Hiroaki Ikematsu

Shiga University of Medical Science

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tomonori Yano

Jichi Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge